908 Devices Inc.

49 articles with 908 Devices Inc.

• 908 Devices Showcases Technology for Accelerating Mass Spec Workflows in Presentations at ASMS

  6/2/2022

  908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70th American Society for Mass Spectrometry (ASMS) Conference June 5-9 in Minneapolis.

• 908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference

  5/26/2022

  908 Devices to Participate in the William Blair 42nd Annual Growth Stock Conference.

• 908 Devices Reports First Quarter 2022 Financial Results and Reiterates 2022 Revenue Outlook

  5/10/2022

  908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today reported financial results for the quarter ended March 31, 2022.

• 908 Devices Advances MX908 Handheld Device Capabilities

  5/9/2022

  908 Devices Inc. today announced updates to its MX908 handheld mass spec device, adding new capabilities to streamline workflows and improve field safety for first responders.

• 908 Devices Partners with Key Biomanufacturing Innovation Center

  5/3/2022

  908 Devices is partnering with the Advanced Mammalian Biomanufacturing Innovation Center (AMBIC), an academic-industry research consortium dedicated to implementing bioengineering innovations that enhance the development and manufacture of complex biotherapeutics.

• 908 Devices and CPI Team on Cell Culture Media Optimization for Improved Process Control in Bioprocessing Applications

  4/21/2022

  908 Devices is collaborating with UK-based, deep-tech innovation organization CPI on a project to optimize mammalian cell culture media and feeding strategies to improve growth, protein titer and protein quality attributes.

• 908 Devices to Report First Quarter Financial Results on May 10, 2022

  4/12/2022

  908 Devices Inc. today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 10, 2022.

• 908 Devices Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 Revenue Outlook

  3/7/2022

  908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, reported financial results for the quarter and full year ended December 31, 2021.

• 908 Devices Appoints Tony J. Hunt, President and CEO, Repligen, to its Board of Directors

  3/2/2022

  908 Devices, a pioneer of purpose-built handheld and desktop mass spectrometry devices for chemical and biomolecular analysis, has appointed Tony J. Hunt, President and CEO, Repligen Corporation, to serve on its Board of Directors effective immediately.

• 908 Devices to Report Fourth Quarter and Full Year 2021 Financial Results on March 7, 2022

  2/15/2022

  908 Devices Inc. today announced it will report financial results for the fourth quarter and full year 2021 after market close on Monday, March 7, 2022.

• 908 Devices to Participate in Upcoming Investor Conferences - Feb 08, 2022

  2/8/2022

  908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced it will participate in the following virtual investor conferences.

• 908 Devices Announces Preliminary Revenue for the Fourth Quarter and Full Year 2021

  1/10/2022

  908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, announced preliminary, unaudited revenue for the fourth quarter and full year ended December 31, 2021.

• 908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer

  1/7/2022

  908 Devices today announced that GlaxoSmithKline (NYSE: GSK) has purchased an additional REBEL ™ cell culture media analyzer.

• 908 Devices and U.S. Forest Service Announce Development Collaboration

  1/4/2022

  908 Devices and the United States Forest Service (USFS), an agency of the United States Department of Agriculture (USDA), are collaborating on a research effort to extend the capabilities of the MX908 handheld device for rapid detection of toxic pesticides used in illegal marijuana grows on federal lands.

• 908 Devices Teams With World-Renowned Guardian Centers of Georgia for First Responder Training

  12/22/2021

  Premier CBRNE training facility uses 908 Devices MX908 portable mass spec devices for trace detection of hazardous chemicals.

• 908 Devices Reports Third Quarter 2021 Financial Results

  11/4/2021

  908 Devices Inc., a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, reported financial results for the quarter ended September 30, 2021.

• 908 Devices Launches Oligos Kit for its ZipChip CE-MS Device

  11/1/2021

  908 Devices Inc. announced at the American Society for Mass Spectrometry (ASMS) conference today a new Oligos assay kit for its ZipChip device that enables fast and accurate identification and quantitation of oligonucleotides.

• 908 Devices to Exhibit at ASMS and Present Key Developments in Accelerating Proteomics Workflows

  10/27/2021

  At the American Society of Mass Spectrometry (ASMS) conference October 31 to November 4 in Philadelphia, 908 Devices Inc. (Nasdaq: MASS) is presenting several talks and posters on the use of high-pressure mass spectrometry and microfluidics separation technologies to accelerate drug discovery workflows, including in metabolomics and proteomics applications.

• 908 Devices to Report Third Quarter Financial Results on November 4, 2021

  10/21/2021

  908 Devices Inc. today announced it will report financial results for the third quarter 2021 before market open on Thursday, November 4, 2021.

• 908 Devices Reports Second Quarter 2021 Financial Results and Raises 2021 Revenue Outlook

  8/4/2021

  908 Devices Inc. today reported financial results for the quarter ended June 30, 2021.